Abstract
The importance of matrix metalloproteinases (MMPs) in the growth and spread of solid tumors has been known for over a decade (1,2). However, the molecular mechanisms that regulate their expression and the elucidation of their role in angiogenesis are subjects of extensive, ongoing investigation. The MMPs are a family of extracellular, zinc-dependent proteinases that control tumor growth via tumor promotion (3) and angiogenesis (2,4). They are secreted as latent proenzymes and become activated after cleavage of their propeptide domain. MMPs are regulated on several levels including transcription, protein activation, and the interaction with endogenous inhibitors such as the tissue inhibitors of metalloproteinases (TIMPs) (5). Over 20 MMPs have been described to date (6; see Table 1). Although traditionally subclassified according to substrate specifi city (e.g., collagenases, gelatinases, stromelysins), collectively they are capable of breaking down all of the components of the extracellular matrix (ECM), including components of basement membranes (BMs) and submucosa (1,5,6). MMP-2 and MMP-9, gelatinase A and B, respectively, are of particular interest because they degrade type IV collagen, the major component of basement membranes. Recently, Fang et al. (7) demonstrated in an animal model of chondrosarcoma that MMP-2 shifts the “proteolytic balance” towards an angiogenic phenotype, and is required for new blood vessel formation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mignatti, P. and Rifkin, D. B. (1993) Biology and biochemistry of proteinases in tumor invasion. Physiolog. Rev. 73, 161–195.
Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327–336.
Matrisian, L. (1999) Cancer biology: extracellular proteinases in malignancy. Curr. Biol. 9, R776–R778.
Bergers, G., Javaherian, K., Lo, K-M., Folkman, J., and Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812.
Kleiner, D. E. and Stetler-Stevenson, W. G. (1999) Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43(p), S42–S51.
Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. (2000) Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18 1145–1149.
Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G., et al. (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA 97 3884–3889.
Muller, D., Breathnach, R., Engelmann, A., Millon, R., Bronner, G., Flesch, H., et al. (1991) Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer 48, 550–556.
Nakagawa, H. and Yagihashi, S. (1994) Expression of type IV collagen and its degrading enzymes in squamous carcinoma of the lung. Japn. J. Cancer Res. 85, 934–938.
Garbisa, S., Scagliotti, G., Masiero, L., DiFrancesco, C., Caenazzo, C., Onisto, M., et al. (1992) Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 52, 4548–4549.
Delebecq, T. J., Porte, H., Zerimach, F., Copin, M. C., Gouyer, V., Dacquembronne, E., et al. (2000) Overexpression level of stromelysin 3 is related to lymph node involvement in non-small cell lung cancer. Clin. Cancer Res. 6, 1086–1092.
Nawrocki, B., Polette, M., Marchand, V., Monteau, M., Gillery, P., Tournier, J.-M., and Birembaut, P. (1997) Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int. J. Cancer 72, 556–564.
Trump, B. F., Dowell, E. M., Glaxin, F., Barret, L. A., Becci, P. J., Schurch, W., et al. (1978) The respiratory epithelium. III. Histogenesis of epidermoid metaplasia and carcinoma in situ in the human. J. Natl. Cancer Inst. 61, 563–575.
Bolon, I., Brambilla, E., Vandenbunder, B., Robert, C., Lantuejoul, S., and Brambilla, C. (1996) Changes in the expression of matrix proteases and of transcription factor c-ets-1 during progression of precancerous bronchial lesions. Lab. Investig. 75.
llis, S. M., Nabeshima, K., and Biswas, C. (1989) Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. Cancer Res. 49, 3385–3391.
Prescott, J., Troccoli, N., and Biswas, C. (1989). Coordinate increase in collagenase mRNA and enzyme levels in human fibroblasts treated with tumor cell factor, TCSF. Biochem. Intl. 19, 257–266.
Kataoka, H., DeCastro, R., Zucker, S., and Biswas, C. (1993) Tumor cell-derived collagenase stimulating factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res. 53, 3154–3158.
Lim, M., Martinez, T., Jablons, D., Cameron, R., Guo, H., Toole, B., et al. (1998) Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 441, 88–92.
Bolon, I., Devouassoux, M., Robert, C., Moro, D., Brambilla, C., and Brambilla, E. (1997) Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am. J. Pathol. 150, 1619–1629.
nderson, I. C., Shipp, M. A., Docherty, A. J. P., and Teicher, B. A. (1996) Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 56, 715–718.
Prontera, C., Mariani, B., Rossi, C., Poggi, A., and Rotilio, D. (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastasis in mice bearing Lewis lung carcinoma. Int. J. Cancer 81, 761–766.
Itoh, T., Tanioka, T., Matsuda, H., Nishimoto, H., Yoshioka, T., Suzuki, R., and Uehira, M. (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Mets. 17, 177–181.
Brown, P. D. and Giavazzi, R. (1995) Matrix metalloproteinase inhibition: a review of antitumor activity. Ann. Oncol. 6, 967–974.
Yip, D., Ahmad, A., Karapetis, C. S., Hawkins, C. A., and Harper, P. G. (1999) Matrix metalloproteinase inhibitors: applications in oncology. Invest. New Drugs 17, 387–399.
Parsons, S. L., Watson, S. A., and Steele, R. J. (1997) Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J.Surg. Oncol. 23, 526–531.
Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., Braybrooke, J. P., Long, L., Gleeson, F., et al. (1999) Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5 513–520.
Steward, W. P. (1999) Marimastat (BB2516): current status and development. Cancer Chemother. Pharmacol. 43(p), S56–S60.
Wojtowicz-Praga, S., Torri, J., Johnson, M., Steen, V., Marshall, J., Ness, E., et al. (1998) Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16, 2150–2156.
British Biotech PLC. (1999) Results of marimastat trial 128-pancreatic cancer monotherapy trial. Press release, February.
British Biotech PLC. (2000) Results of marimastat study 193 in advanced pancreatic cancer. Press release, January.
British Biotech PLC. (1999) Results of marimastat study 145 in gastric cancer. Press release, August.
Shalinsky, D. R., Shetty, B., Pithavala, Y., Bender, S., Neri, A., Webber, S., et al. (2000) Prinomastat: a selective matrix metalloprotease inhibitor-preclinical and clinical development for oncology, in Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy (Clendennin, N. J. and Appelt, K., eds.), Humana Press, Inc., Totowa, NJ, pp. 143–173.
Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C.D., Forsyth, P., Edwards, D., et al. (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NYAcad. Sci. 878, 236–270.
Shalinsky, D. R., Brekken, J., Zou, H., Bloom, L. A., McDermott, C. D., Zook, S., et al. (1999) Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. 5, 1905–1917.
Agouron Pharmaceuticals, Inc. (2000) Pfizer discontinues phase III trials of prinomastat in advanced cancers but continues multiple phase II trials. Press release, August 4. New York and La Jolla, CA www.agouron.com/pages/press_releases/ pr080400.html
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Lim, M., Jablons, D.M. (2003). Matrix Metalloproteinase Expression in Lung Cancer. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 74. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-323-2:349
Download citation
DOI: https://doi.org/10.1385/1-59259-323-2:349
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-985-8
Online ISBN: 978-1-59259-323-1
eBook Packages: Springer Protocols